GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » e-Therapeutics PLC (LSE:ETX) » Definitions » Insider Ownership

e-Therapeutics (LSE:ETX) Insider Ownership : 13.91 % (As of Sep. 22, 2024)


View and export this data going back to 2007. Start your Free Trial

What is e-Therapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, e-Therapeutics's insider ownership is 13.91%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, e-Therapeutics's Institutional Ownership is 2.44%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, e-Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.


e-Therapeutics Insider Ownership Historical Data

The historical data trend for e-Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

e-Therapeutics Insider Ownership Chart

e-Therapeutics Historical Data

The historical data trend for e-Therapeutics can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Insider Ownership 13.93 13.93 13.90 13.90 13.90 13.90 13.91 13.91 13.91 13.91

e-Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


e-Therapeutics Business Description

Traded in Other Exchanges
Address
4 Kingdom Street, Paddington, London, GBR, W2 6BD
e-Therapeutics PLC is a drug discovery company. Its ambition is to transform the drug discovery process, leveraging its computational network biology platform (drug discovery) to find novel targets to address mechanisms underpinning complex disease. l company activities are carried out in the UK.

e-Therapeutics Headlines